Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zura Bio Limited - Class A Ordinary shares
(NQ:
ZURA
)
5.370
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zura Bio Limited - Class A Ordinary shares
< Previous
1
2
3
4
Next >
Zura Bio Reports Business Updates and Outlook for 2026
January 12, 2026
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
November 13, 2025
From
Zura Bio Limited
Via
Business Wire
Unusual volume stocks are being observed in Wednesday's session.
↗
October 01, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via
Chartmill
Here are the top movers in Tuesday's session.
↗
September 30, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 30, 2025
Via
Benzinga
These stocks are moving in today's session
↗
September 30, 2025
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
September 29, 2025
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44....
Via
Benzinga
Top stock movements in today's session.
↗
September 29, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
September 29, 2025
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
September 29, 2025
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
Via
Benzinga
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
↗
September 29, 2025
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its...
Via
Benzinga
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
August 20, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
August 14, 2025
From
Zura Bio Limited
Via
Business Wire
Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well
↗
August 11, 2025
Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.
Via
Stocktwits
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2025
From
Zura Bio
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
July 17, 2025
Via
Benzinga
Zura Bio Announces Chief Financial Officer Transition
July 01, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Present at the Jefferies Global Healthcare Conference
May 27, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
May 20, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates
May 08, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
March 25, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
February 24, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
December 23, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
November 14, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
November 07, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Participate in Two Upcoming Investor Conferences in November
October 30, 2024
From
Zura Bio
Via
Business Wire
Zura Bio to Present at Three Upcoming Investor Conferences in September
September 03, 2024
From
Zura Bio Limited
Via
Business Wire
ZURA Stock Earnings: Zura Bio Misses EPS for Q2 2024
↗
August 13, 2024
ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From
Zura Bio Limited
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
